2839. Efficacy, Pharmacokinetics (PK), and Safety Profile of Suvratoxumab (MEDI4893), a Staphylococcus aureus Alpha Toxin (AT)-Neutralizing Human Monoclonal Antibody in Mechanically Ventilated Patients in Intensive Care Units; Results of the Phase 2 SAATELLITE Study Conducted by the Public-Private COMBACTE Consortium

BACKGROUND: Staphylococcus aureus (SA) pneumonia imposes significant morbidity and mortality in mechanically ventilated, intensive care unit (MV ICU) patients despite best clinical care. We assessed efficacy, PK, AT-neutralizing antibodies (AT NAbs), and safety of suvratoxumab (suvra) in MV ICU subj...

Descripción completa

Detalles Bibliográficos
Autores principales: Francois, Bruno, Sánchez Garcia, Miguel, Eggimann, Philippe, Dequin, Pierre-Francois, Laterre, Pierre-François, Huberlant, Vincent, Viña Soria, Lucia, Boulain, Thierry, Bretonnière, Cédric, Pugin, Jerome, Trenado Álvarez, José, Catalina Hernandez Padilla, Ana, Coenjaerts, Frank, Ali, Omar, Shoemaker, Kathryn, Ruzin, Alexey, Pierre, Vadryn, Wu, Yuling, Colbert, Susan, McCarthy, Michael, Dubovsky, Filip, S. Jafri, Hasan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809370/
http://dx.doi.org/10.1093/ofid/ofz359.144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809370/
http://dx.doi.org/10.1093/ofid/ofz359.144

Ejemplares similares